InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$18.60+0.25 (+1.36%)
Close on Nov 13, 2026Market cap $102.18MP/E –Yield –
InMed Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
InMed Pharmaceuticals's total assets was $1.31M at Sep 30, 2026. For fiscal 2026 it was $3.03M, down 80.6% from the year before. The highest annual figure on record is $15.58M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $3.03M | -80.6% |
| FY2025 | Jun 30, 2025 | $15.58M | +31.8% |
| FY2024 | Jun 30, 2024 | $11.82M | -16.2% |
| FY2023 | Jun 30, 2023 | $14.11M | +10.3% |
| FY2022 | Jun 30, 2022 | $12.79M | +30.7% |
| FY2021 | Jun 30, 2021 | $9.78M | +25.4% |
| FY2020 | Jun 30, 2020 | $7.80M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $1.31M | -90.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $3.03M | -80.6% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $9.13M | -1.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $11.19M | +31.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $13.36M | +27.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $15.58M | +31.8% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $9.28M | -30.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $8.50M | -44.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $10.47M | -4.1% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $11.82M | -16.2% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $13.36M | -9.3% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $15.26M | -9.8% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $10.92M | -25.1% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $14.11M | +10.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $14.73M | -4.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $16.92M | -12.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $14.58M | -15.8% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $12.79M | +30.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $15.49M | +25.4% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $19.38M | +65.0% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $17.33M | +162.4% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $9.78M | +25.4% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $12.34M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $11.75M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $6.60M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $7.80M | – |
See a number that looks wrong?